Classical Galactosemia: Biochemical Basis of Clinical Signs and Symptoms

The Enzyme Defect and Metabolic Block

Galactose
   ↓  [Galactokinase (GALK)]
Galactose-1-phosphate (Gal-1-P)
   ↓  [GALT] ← BLOCKED IN CLASSICAL GALACTOSEMIA
UDP-galactose + Glucose-1-phosphate
   ↓  [UDP-galactose 4'-epimerase (GALE)]
UDP-glucose

• Galactitol: galactose is reduced by aldose reductase → galactitol (a polyol that cannot be further metabolised and becomes trapped in tissues)
• Galactonate: an oxidized by-product of excess galactose

Biochemical Mechanisms Behind Each Clinical Feature

1. Neonatal Presentation: Vomiting, Diarrhea, Failure to Thrive

2. Jaundice and Hepatomegaly (first week of life)

• Early hepatomegaly is caused primarily by fatty change (steatosis) - Gal-1-P disrupts normal lipid metabolism in hepatocytes.
• Prolonged or severe disease leads to widespread hepatic scarring resembling alcoholic cirrhosis - Gal-1-P accumulation causes direct hepatocyte toxicity, oxidative stress (greater oxidative stress is associated with low GALT activity), and possibly mitochondrial dysfunction (see below).
• Jaundice may appear to continue from physiologic neonatal jaundice, but is actually unconjugated + conjugated hyperbilirubinemia from hepatocellular damage.
• Coagulopathy (easy bruisability, bleeding) follows from impaired hepatic synthesis of clotting factors.
• Hypoalbuminemia, ascites, and anasarca develop as liver synthetic function deteriorates.

3. Cataracts

4. Intellectual Disability / Brain Damage

5. Aminoaciduria / Renal Fanconi Syndrome

• Aminoaciduria
• Albuminuria and aciduria
• Glycosuria (glucose reabsorption failure)
• Metabolic acidosis

6. E. coli Septicemia (Neonatal)

7. Premature Ovarian Failure (Long-term)

• Defective glycosylation - UDP-galactose deficiency impairs glycoprotein synthesis, including glycosylation of FSH and its receptor, disrupting gonadotropin signalling
• Defective germ cell migration - galactose metabolites may impair embryonic germ cell migration to the developing gonads during fetal development, reducing the initial oocyte pool
• Direct gonadal toxicity of Gal-1-P in ovarian tissue (streak ovaries are found on histology)
• Notably, testicular function is not significantly affected in males

8. Ataxia and Speech Defects (Long-term, even on treatment)

• Cerebellar damage (dentate nuclei) occurs early and may not fully reverse
• The UDP-galactose deficit may have caused irreversible impairment of myelin and glycoprotein formation during critical developmental windows
• Endogenous galactose production (from turnover of glycoproteins/glycolipids) continues even on a galactose-free diet, meaning low-level Gal-1-P accumulation is never fully eliminated

Summary Diagram

GALT deficiency
       │
       ├─→ Gal-1-P accumulates ────┬─→ Liver: steatosis → cirrhosis → jaundice, coagulopathy
       │                           ├─→ Brain: neurotoxicity + poor ATP → cognitive impairment, ataxia
       │                           ├─→ Kidney: tubular dysfunction → Fanconi syndrome
       │                           ├─→ Neutrophils: impaired killing → E. coli sepsis
       │                           ├─→ Ovaries: streak ovaries → premature ovarian failure
       │                           └─→ Mitochondria: cytochrome c oxidase inhibition → ATP depletion
       │
       ├─→ Galactitol accumulates ──→ Lens: osmotic swelling → cataract
       │
       └─→ UDP-galactose deficit ──→ Impaired glycoprotein/glycolipid synthesis
                                      → CNS: defective myelin, FSH glycosylation defect

Sources

• Robbins, Cotran & Kumar Pathologic Basis of Disease (10th ed.), p. 440
• Robbins & Kumar Basic Pathology, Galactosemia section
• Henry's Clinical Diagnosis and Management by Laboratory Methods, Defects in Galactose Metabolism
• Basic Medical Biochemistry (6th ed.)
• Emery's Elements of Medical Genetics and Genomics
• Machado CM et al. (2024). Galactose-1-phosphate inhibits cytochrome c oxidase and causes mitochondrial dysfunction in classic galactosemia. Biochim Biophys Acta Mol Basis Dis. PMID 38986816
• Teixeira LF et al. (2024). Classical Hereditary galactosemia: findings in patients and animal models. Metab Brain Dis. PMID 37702899

Classical Galactosemia: Biochemical Basis of Clinical Signs and Symptoms

The Metabolic Pathway and the Block

The Metabolic Pathway Diagram

Toxic Metabolites That Accumulate

Biochemical Explanation of Each Clinical Sign/Symptom

1. Failure to Thrive, Vomiting, Diarrhea (within days of first milk feed)

• Mechanism: Gal-1-P is a phosphate trap - it sequesters inorganic phosphate, depleting the cell of the phosphate needed for ATP synthesis, glycolysis, and gluconeogenesis.
• Gal-1-P also inhibits phosphoglucomutase, the enzyme that converts glucose-1-phosphate to glucose-6-phosphate, thereby impairing glycogenolysis and gluconeogenesis.
• The result is cellular energy failure in liver and intestinal cells, causing feeding intolerance. Symptoms start as soon as the infant ingests breast milk or milk-based formula - seen as early as the second day of life.

2. Jaundice and Hepatomegaly (first week of life)

• Early: Gal-1-P accumulation in hepatocytes causes fatty change (steatosis) by disrupting normal lipid metabolism. The liver enlarges from fat-laden cells.
• Later: Direct toxicity of Gal-1-P to hepatocytes leads to cell death, inflammation, and widespread hepatic fibrosis/cirrhosis (resembling alcoholic cirrhosis).
• Jaundice is both unconjugated (from hemolysis - see below) and conjugated (from hepatocellular damage with impaired bilirubin conjugation and excretion).
• Coagulopathy / easy bruisability: Damaged liver fails to synthesize clotting factors (factors II, VII, IX, X). Newborn screening must be done promptly because hepatic failure is rapidly progressive.

3. Cataracts

1. Excess galactose in blood enters the lens of the eye (which lacks GALT and is essentially a galactose sink).
2. In the lens, galactose is reduced by aldose reductase to galactitol (using NADPH as cofactor).
3. Aldose reductase has a relatively high Km for galactose (~12-20 mM), so galactitol is only formed when galactose levels are substantially elevated, as in galactosemia.
4. Galactitol cannot be further metabolised (there is no pathway to process it) and diffuses out of the lens very slowly - it becomes trapped.
5. The accumulated galactitol creates a hyperosmotic state inside lens cells, drawing water in. The lens swells, and fiber cells rupture - producing opacification (cataract).

"Aldose reductase has a relatively high Km for galactose, approximately 12-20 mM, so galactitol is formed only in galactosemic patients who have eaten galactose. Galactitol is not further metabolized and diffuses out of the lens very slowly. Thus, hypergalactosemia is even more likely to cause cataracts than hyperglycemia."

• Basic Medical Biochemistry, 6th ed.

4. Intellectual Disability / Brain Damage

"One of the most serious problems of classical galactosemia is irreversible intellectual disability."

• Basic Medical Biochemistry, 6th ed.

5. Aminoaciduria / Renal Fanconi Syndrome

• Gal-1-P accumulates in renal proximal tubular cells, impairing the sodium-dependent amino acid transporters on the luminal membrane.
• The result is generalised proximal tubular dysfunction: aminoaciduria, albuminuria, glycosuria, and metabolic acidosis (renal Fanconi syndrome).
• Urine is positive for a reducing sugar (galactose) but negative for glucose on glucose-oxidase test - a key diagnostic clue. A non-glucose reducing sugar in urine of a sick neonate should immediately raise suspicion for galactosemia.

6. E. coli Septicemia (Neonatal)

• Gal-1-P accumulation in neutrophils and other leukocytes impairs their bactericidal function (oxidative burst / phagocytic killing capacity).
• There is an abnormality in leukocyte function during the neonatal period, increasing susceptibility to Gram-negative sepsis, particularly Escherichia coli.
• This is especially dangerous because the onset of sepsis may actually precede the clinical diagnosis of galactosemia.

7. Hemolysis and Coagulopathy

• Gal-1-P accumulates in red blood cells (RBCs contain GALT normally; in its absence, Gal-1-P builds up).
• RBC membrane function is disrupted, leading to hemolysis, which worsens the jaundice.
• Coagulopathy arises from hepatic failure (impaired synthesis of clotting factors).

8. Premature Ovarian Failure (Long-term, even on treatment)

1. UDP-galactose deficiency impairs glycoprotein synthesis: FSH and its receptor are glycoproteins. Defective glycosylation (because UDP-galactose is unavailable) impairs FSH receptor expression and signalling on ovarian follicles, disrupting oocyte maturation. This leads to hypergonadotropic hypogonadism (high FSH, low estrogen).
2. Direct gonadotoxicity: Gal-1-P and galactitol accumulate in ovarian tissue, possibly impairing embryonic germ cell migration and causing early follicle depletion. "Streak ovaries" are found histologically.

9. Hypoglycemia

• Gal-1-P inhibits phosphoglucomutase, which is needed to release glucose from glycogenolysis (glycogen → glucose-1-P → glucose-6-P → glucose).
• It also inhibits gluconeogenesis.
• Hypoglycemia is not prominent unless there is liver failure, at which point gluconeogenesis fails completely.

Summary Table (Biochemistry-First View)

Sources

• Basic Medical Biochemistry: A Clinical Approach, 6th ed. - Chapters 22 & 27 (Galactose Metabolism; Clinical Comments, Erin G. case)
• Lippincott Illustrated Reviews: Biochemistry, 8th ed. - Chapter 12 (Fructose and Galactose Metabolism), pp. 414-416
• Harrison's Principles of Internal Medicine, 22nd ed. (2025) - Chapter 430, Galactosemia Type I
• Henry's Clinical Diagnosis and Management by Laboratory Methods - Defects in Galactose Metabolism